Cargando…
Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids
BACKGROUND: Recurrence of retinoblastoma (RB) following chemoreduction is common and is often managed with local (intra-arterial/intravitreal) chemotherapy. However, some tumors are resistant to even local administration of maximum feasible drug dosages, or effective tumor control and globe preserva...
Autores principales: | Srimongkol, Atthapol, Laosillapacharoen, Natanan, Saengwimol, Duangporn, Chaitankar, Vijender, Rojanaporn, Duangnate, Thanomchard, Thanastha, Borwornpinyo, Suparerk, Hongeng, Suradej, Kaewkhaw, Rossukon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890748/ https://www.ncbi.nlm.nih.gov/pubmed/36726110 http://dx.doi.org/10.1186/s13046-023-02608-1 |
Ejemplares similares
-
Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation
por: Saengwimol, Duangporn, et al.
Publicado: (2020) -
A three-dimensional organoid model recapitulates tumorigenic aspects and drug responses of advanced human retinoblastoma
por: Saengwimol, Duangporn, et al.
Publicado: (2018) -
Germline RB1 Mutation in Retinoblastoma Patients: Detection Methods and Implication in Tumor Focality
por: Rojanaporn, Duangnate, et al.
Publicado: (2022) -
Spectrum of germline RB1 mutations and clinical manifestations in retinoblastoma patients from Thailand
por: Rojanaporn, Duangnate, et al.
Publicado: (2018) -
Retinoblastoma: Etiology, Modeling, and Treatment
por: Kaewkhaw, Rossukon, et al.
Publicado: (2020)